X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with Elder Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs ELDER PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA ELDER PHARMA AJANTA PHARMA/
ELDER PHARMA
 
P/E (TTM) x 20.1 -0.2 - View Chart
P/BV x 8.7 0.1 8,627.5% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 AJANTA PHARMA   ELDER PHARMA
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-16
ELDER PHARMA
Jun-14
AJANTA PHARMA/
ELDER PHARMA
5-Yr Chart
Click to enlarge
High Rs1,720380 452.6%   
Low Rs1,103188 586.7%   
Sales per share (Unadj.) Rs194.6491.2 39.6%  
Earnings per share (Unadj.) Rs45.2-3.2 -1,421.3%  
Cash flow per share (Unadj.) Rs50.314.4 349.1%  
Dividends per share (Unadj.) Rs8.000-  
Dividend yield (eoy) %0.60-  
Book value per share (Unadj.) Rs132.0376.5 35.1%  
Shares outstanding (eoy) m88.7720.54 432.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.30.6 1,254.5%   
Avg P/E ratio x31.2-89.3 -35.0%  
P/CF ratio (eoy) x28.119.7 142.4%  
Price / Book Value ratio x10.70.8 1,417.3%  
Dividend payout %17.70-   
Avg Mkt Cap Rs m125,2995,833 2,148.0%   
No. of employees `000NANA-   
Total wages/salary Rs m2,5702,179 117.9%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m17,27510,089 171.2%  
Other income Rs m166257 64.8%   
Total revenues Rs m17,44210,346 168.6%   
Gross profit Rs m5,807-792 -733.3%  
Depreciation Rs m451361 124.7%   
Interest Rs m492,756 1.8%   
Profit before tax Rs m5,474-3,653 -149.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m03,713 0.0%   
Tax Rs m1,460125 1,166.5%   
Profit after tax Rs m4,014-65 -6,142.5%  
Gross profit margin %33.6-7.8 -428.3%  
Effective tax rate %26.7-3.4 -778.4%   
Net profit margin %23.2-0.6 -3,587.3%  
BALANCE SHEET DATA
Current assets Rs m7,6399,240 82.7%   
Current liabilities Rs m2,7159,998 27.2%   
Net working cap to sales %28.5-7.5 -379.5%  
Current ratio x2.80.9 304.5%  
Inventory Days Days4346 93.3%  
Debtors Days Days7960 131.3%  
Net fixed assets Rs m6,91410,124 68.3%   
Share capital Rs m177206 86.0%   
"Free" reserves Rs m11,4425,582 205.0%   
Net worth Rs m11,7217,734 151.6%   
Long term debt Rs m1494,889 3.0%   
Total assets Rs m14,81422,882 64.7%  
Interest coverage x112.9-0.3 -34,720.5%   
Debt to equity ratio x00.6 2.0%  
Sales to assets ratio x1.20.4 264.5%   
Return on assets %27.411.8 233.2%  
Return on equity %34.2-0.8 -4,052.9%  
Return on capital %46.522.3 208.6%  
Exports to sales %55.13.0 1,814.7%   
Imports to sales %6.00.4 1,406.0%   
Exports (fob) Rs m9,527307 3,107.3%   
Imports (cif) Rs m1,03843 2,407.4%   
Fx inflow Rs m10,422307 3,399.2%   
Fx outflow Rs m1,678125 1,339.3%   
Net fx Rs m8,744181 4,822.7%   
CASH FLOW
From Operations Rs m3,26411,754 27.8%  
From Investments Rs m-2,093-561 373.4%  
From Financial Activity Rs m-1,186-6,762 17.5%  
Net Cashflow Rs m-154,432 -0.3%  

Share Holding

Indian Promoters % 73.8 39.6 186.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.6 7.5 20.7%  
FIIs % 7.6 16.8 45.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 36.1 47.1%  
Shareholders   20,968 16,479 127.2%  
Pledged promoter(s) holding % 4.4 77.6 5.7%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   PANACEA BIOTECH  DISHMAN PHARMA  UNICHEM LAB  NATCO PHARMA  DIVIS LABORATORIES  

Compare AJANTA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Post Noon Sell-Off; Infosys Falls 5.4%(Closing)

Share markets in India witnessed a sharp fall in the final minutes of trade. At the closing bell, the BSE Sensex closed lower by 266 points. While, the NSE Nifty finished lower by 83 points.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

Aug 8, 2017

'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Aug 21, 2017 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA - MERCK LTD COMPARISON

COMPARE AJANTA PHARMA WITH

MARKET STATS